Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
BMS' Zeposia comes up short in Crohn's disease study
Interim analysis of Bristol Myers Squibb’s 12-week induction trial of Zeposia in Crohn’s disease has failed to achieve its primary endpoint.
Kevin Dunleavy
Mar 29, 2024 8:15am
Sponsored
BioDesign: Accelerating the Momentum of Bioconjugate Therapeutics
Mar 25, 2024 8:00am
Genmab to expand in New Jersey in bid to boost Epkinly rollout
Mar 28, 2024 4:29pm
Amneal pulls 4 lots of potentially overfilled antibiotic bottles
Mar 28, 2024 2:59pm
US judge will allow J&J to contest science in talc litigation
Mar 28, 2024 12:52pm
Regulatory tracker: Keytruda wins EU nod in perioperative NSCLC
Mar 28, 2024 11:20am
Manufacturing News
WuXi AppTec allegedly handed over client's IP to China: report
Mar 28, 2024 10:21am
Abzena earmarks $5M to bolster ADC services at Pennsylvania site
Mar 28, 2024 8:40am
WuXi Biologics stays the course with positive 2024 outlook
Mar 27, 2024 1:44pm
AZ plans separate drug supply chains for US and China, CEO says
Mar 27, 2024 12:27pm
See More Manufacturing News